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1. INTRODUCTION 
 
1.1 BLADDER CANCER 
 
Bladder cancer is any of several types of malignancy arising from the epithelial lining (i.e., 
the urothelium) of the urinary bladder. Rarely the bladder is involved by non-epithelial 
cancers, such as lymphoma or sarcoma, but these are not ordinarily included in the colloquial 
term "bladder cancer." It is a disease in which abnormal cells multiply without control in the 
bladder. The bladder is a hollow, muscular organ that stores urine; it is located in the pelvis. 
The most common type of bladder cancer recapitulates the normal histology of the 
urothelium and it is known as transitional cell carcinoma or more properly urothelial cell 
carcinoma. It is estimated that there are 383.000 cases of bladder cancer worldwide1. 
Detection and monitoring of  bladder cancer is usually done by urine cytology, cystoscopy  
and histology2. However these methods are highly subjective, expensive,  invasive  and often 
are not able to reveal low-grade bladder cancer at the first stage of transformation (urine 
cytology), flat bladder cancer in situ and bladder cancer which remain below the mucosa 
surface (cystoscopy). Non-invasive methods which are able to compete with cystoscopy and 
to implement cytology diagnostic accuracy are still needed. In recent years some non-
invasive test performed on voided urine have been developed for the early detection of 
bladder cancer. However these biomarkers require to be validated in further studies. The aim 
of this study was to verify the accuracy of new molecular non invasive test in the diagnosis 
of bladder cancer.  
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1.2 EPIDEMIOLOGY 
 
In the United States, bladder cancer is the fourth most common type of cancer in men and the 
ninth most common cancer in women3. Fifty thousand new cases with bladder cancer are 
diagnosed each year, even if the mortality is not so high (Figure 1). Smoking can only 
partially explain this higher incidence in men4. One other reason is that the androgen 
receptor, which is much more active in men than in women, plays a major part in the 
development of the cancer5.  
 
Figure 1. Bladder cancer incidence and mortality (yr 2000). 
1.3 RISK FACTORS 
 
Tobacco smoking is the main known contributor to urinary bladder cancer; in most 
populations, smoking is associated with over half of bladder cancer cases in men and one-
third of cases among women6. There is a linear relationship between smoking and risk, and 
New cases 
deaths 
[
[
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quitting smoking reduces the risk7. Passive smoking has not been proven to be involved8. In a 
10-year study involving almost 48.000 men, researchers found that men who drank 1.5 liters 
of water per day had a significantly reduced incidence of bladder cancer when compared with 
men who drank less than 240 mL (around 1 cup) per day. The authors proposed that bladder 
cancer might partly be caused by the bladder directly contacting carcinogens that are 
excreted in urine, although this has not yet been confirmed in other studies9. Thirty percent of 
bladder tumours probably result from occupational exposure in the workplace to carcinogens 
such as benzidine. 2-Naphthylamine, which is found in cigarette smoke, has also been shown 
to increase bladder cancer risk. Occupations at risk are bus drivers, rubber workers, motor 
mechanics, leather (including shoe) workers, blacksmiths, machine setters, and mechanics10. 
Hairdressers are thought to be at risk as well because of their frequent exposure to permanent 
hair dyes. It has been suggested that some gene mutations (i.e HRAS, KRAS2, RB1, and 
FGFR3) may be associated with bladder cancer in some cases11. 
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1.4 ANATOMO-PATHOLOGICAL FEATURES OF BLADDER CANCER 
 
The urinary bladder leis within the pelvic cavity. The bladder lies behind the symphysis 
pubis.  It is below the parietal peritoneum. Urine produced in the kidneys flows into the 
bladder via the ureters. The urine is ultimately excreted from the bladder through the urethra. 
The innermost portion of the urinary bladder is the mucosa (Figure 2). The histology of the 
mucosa is that it is composed of transitional epithelium and connective tissue. The epithelium 
lies upon connective tissue called the lamina propria. The lamina propria is composed of 
areolar connective tissue. It contains blood vessels, nerves, and, in some regions, glands.           
Ninety percent  of bladder cancers derived from transitional epithelium and then they are 
called transitional cell carcinoma (TCC). The other 10% are squamous cell carcinoma, 
adenocarcinoma, sarcoma, small cell carcinoma, and secondary deposits from cancers 
elsewhere in the body. The pattern of growth of bladder cancer can be papillary, sessile (flat) 
(infiltrating or not infiltrating) or carcinoma in situ (CIS).  
 
Figure 2. Conformation and bladder layers. 
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1.4.1 GRADING AND WHO CLASSIFICATION 
Some controversies arose following the introduction of the 1998 WHO/ISUP classification of 
bladder tumours, mainly because of lack of validation, reproducibility, and translation 
studies. In particular, no sound translation scheme comparing the 1973 with the 1998 (and 
2004) classifications has been put forward. Basically, grade 1 (WHO 1973 classification) 
tumours should be subdivided into PUNLMP and low-grade carcinomas, whereas most grade 
2 and all grade 3 cases are defined as high grade carcinomas. In this scheme, grade 2 
tumours, whose morphology borders with that of grade 1 tumours, become low-grade 
carcinomas12 (Figure 3).  
                            
           Figure 3. Comparison between 1973 and 2004 WHO classifications. 
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WHO classification12 
 
Flat Intraepithelial Lesions 
Urothelium, the dominant type of epithelium lining the urinary bladder, ureter, and renal 
pelvis, has unique characteristics that separate it from all other type of epithelia. The 2004 
WHO classification of the flat lesions includes urothelial hyperplasia, reactive urothelial 
atypia, atypia of unknown significance, dysplasia, and CIS. 
 
Urothelial Hyperplasia, Reactive Urothelial Atypia, and Atypia of Unknown 
Significance 
Urothelial hyperplasia is defined as markedly thickened mucosa without cytologic atypia. 
Flat urothelial hyperplasia historically has been defined as urothelium greater than 7 cells 
layers thick. In practice, counting the number of urothelial cell layers is not reproducible, as 
urothelial cells do not line up in neat rows. 
 
Urothelial Dysplasia 
Dysplasia is an intraurothelial lesion with appreciable cytologic and architectural changes felt 
to be preneoplastic but that fall short of CIS. The morphology of dysplasia generally shows 
cohesive cells characterized by mild nuclear/nucleolar changes that focally include irregular 
nuclear crowding and slight hyperchromasia. 
 
Urothelial Carcinoma in situ 
Carcinoma in situ is a nonpapillary flat  lesion in which the surface epithelium contains cells 
that are cytologically malignant. The morphologic diagnosis of CIS requires the presence of 
severe cytologic atypia (nuclear anaplasia). 
 
Noninvasive Papillary Urothelial Lesions 
This group comprises papilloma, inverted papilloma, papillary urothelial neoplasm of low 
malignant potential, and noninvasive low-grade and high-grade papillary urothelial 
carcinoma. 
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Urothelial Papilloma 
Urothelial papilloma is a benign exophytic neoplasm composed of a delicate fibrovascular 
core covered by normal looking urothelium. 
 
Inverted Papilloma 
Inverted papilloma is a benign urothelial tumour that has an inverted growth pattern with 
normal to minimal cytologic atypia of the cells. 
 
Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP) 
This is a noninvasive papillary urothelial tumour that resembles the exophytic urothelial 
papilloma but shows increased cellularity exceeding the thickness of normal urothelium. 
 
Noninvasive Low-Grade Papillary Urothelial Carcinoma 
This is a neoplasm of urothelium lining papillary fronds that shows an orderly appearance but 
easily recognizable variations in architecture and cytologic features. 
 
Noninvasive High-Grade Papillary Urothelial Carcinoma 
This is a neoplasm of urothelium lining papillary fronds that shows a predominant pattern of 
disorder with moderate-to-marked architectural and cytologic atypia. 
 
Invasive Urothelial Neoplasms 
Lamina Propria Invasion 
Lamina propria invasion is characterized by the presence of neoplastic urothelial nests, 
clusters, or single cells within the lamina propria, often associated with prominent retraction 
artifact. 
 
Muscularis Propria (Detrusor Muscle) Invasion 
The distinction on transurethral resection of muscularis mucosae from muscularis propria 
invasion may occasionally be difficult. 
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1.4.2 STAGING  
The definition of the clinical and pathological stage of bladder cancer is the evaluation of the 
extent of the tumour on the surface, the local progression within the mucosa, submucosa or 
muscular layers of the bladder, and the distance to adjacent areas (Figure 4). Staging is 
particularly critical because of the many prognostic variables. 
The correct staging allows to: 
- determine the spread of the disease to other organs and systems 
- propose the best therapeutic strategy 
- provide prognostic information 
- compare the results of different treatment options 
It is imperative to differentiate between two groups: superficial and infiltrating bladder 
cancer12. In fact, the first group, which comprises 70-80 % of cancers, tends to a local disease 
with a chronic high chance of local recurrence and, except in the forms G3, with low 
tendency to progress. The second group comprises the remaining 20-30% and it is a systemic 
disease that tends to pose a risk to the patient’s life and requires staging and different 
therapies.                                                                                                                           
Clinical staging requires manual palpation under anesthesia before and after resection of 
neoplastic masses, and urography, for advanced forms is required chest x-ray, ultrasound of 
the liver, abdominal and pelvic CT, bone scintigraphy. Urinary cytology is important as it is 
able to highlight, with a diagnostic accuracy of around 90%, the in situ carcinoma. 
There are three classifications used: the Jewett-Strong-Marshall, the Union Internationale 
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Contre le Cancer (TNM) and the American Joint Committee, although currently the TNM 
system is the most used in all countries. The classification of Jewett-Strong- Marshall defines 
the extent of the disease according to five categories (0 to D), while the other two, with slight 
variations, define the parameters (T, N, M). 
T (Primary tumour) 
• TX Primary tumour cannot be assessed 
• T0 No evidence of primary tumour 
• Ta Non-invasive papillary carcinoma 
• Tis Carcinoma in situ (‘flat tumour’) 
• T1 Tumour invades subepithelial connective tissue 
• T2a Tumour invades superficial muscle (inner half) 
• T2b Tumour invades deep muscle (outer half) 
• T3 Tumour invades perivesical tissue: 
• T3a Microscopically 
• T3b Macroscopically (extravesical mass) 
• T4a Tumour invades prostate, uterus or vagina 
• T4b Tumour invades pelvic wall or abdominal wall 
N (Lymph nodes) 
• NX Regional lymph nodes cannot be assessed 
• N0 No regional lymph node metastasis 
• N1 Metastasis in a single lymph node 2 cm or less in greatest dimension 
• N2 Metastasis in a single lymph node more than 2 cm but not more than 5 cm in 
greatest dimension, or multiple lymph nodes, none more than 5 cm in greatest 
dimension 
• N3 Metastasis in a lymph node more than 5 cm in greatest dimension 
M (Distant metastasis) 
• MX Distant metastasis cannot be assessed 
• M0 No distant metastasis 
• M1 Distant metastasis. 
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Figure 4. T Categories proposed by TNM classification. 
 
1.5 MOLECULAR GENETICS 
 
The molecular mechanisms of occurrence and development of transitional cell carcinomas of 
the bladder include interactions between tumour suppressor genes, oncogenes, growth 
factors,  adhesion molecules and angiogenic factors. The resultant of these interactions is the 
acquisition of the malignant phenotype by normal transitional cells. The initiation and the 
development of the tumour is the result of an initial damage that involves a genetic disorder 
both as negation of a tumour suppressor gene is as induction of oncogenes. Tumour 
progression follows the acquisition by the normal cell transformed further development 
                 1: epithelium; 2: connective tissue 
                 3: muscle; 4: perivescical fat 
                                 T CATEGORIES OF TNM CLASSIFICATION 
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capability   (growth factors and angiogenic), as well as the ability to invade and overcome the 
lamina propria (adhesion molecules and motility factors) with the result of the diffusion 
distance. Repeated and sequential stages of initiation and promotion to the selection of cell 
populations increasingly affected. It is thought that the development of bladder cancer is a 
process resulting from the evolutionary stages, passing through the stages of hyperplasia and 
dysplasia to malignant urothelial cell transformed13. 
Cytogenetic studies have revealed both chromosomal abnormalities and specific correlations 
between genetic alterations and biological behavior of the tumour. The most frequent 
combinations of genetic and epigenetic alterations that lead to the development of bladder 
cancer have been already acquired. Molecular pathology could have a role in the further 
refinements of the classification system. The genetic studies so far published have classified 
tumours according to the 1973 WHO scheme, and further studies are needed to link available 
genetic information to the 2004 WHO scheme. Current data suggest 2 genetic 
subtypes/pathways that correspond to morphologically defined entities (Figure 5). 
The genetically stable category includes low-grade noninvasive papillary tumours (pTa, G1, 
and G2), whereas the genetically unstable category contains high-grade (including pTa, G3, 
and CIS) and invasively growing carcinomas (stage pT1-4). Noninvasive low-grade bladder 
neoplasms have only few genomic alterations and are therefore viewed as genetically stable. 
Invasively growing and high-grade neoplasms appear to be genetically unstable and have 
several chromosomal aberrations. There are two distinct molecular pathways that lead to the 
development of low-grade non-invasive and muscle-invasive tumours.  
The origin of high-grade papillary Ta tumours is not yet clear, it is thought to be caused by 
dysplasia or low-grade papillary tumours. Similarly, the way of the development of T1 
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tumours is unclear, but it could be the acquisition of invasive capacity on the part of  high-
grade Ta or carcinoma in situ (Figure 5). 
 The most common alterations of low-grade, non-invasive tumours include the deletion of 
chromosome 9 and the point mutation of the receptor 3 fibroblast growth factor (FGFR3).  
 The muscle-invasive bladder tumours show a broad spectrum of genetic alterations: some 
implicated known genes but also a large number of genetic alterations and changes in the 
number of copies in the regions of the genome yet unknown. Many studies have identified 
the RB1 and TP53 tumour suppressor genes, which are altered in the majority of these 
tumours. The involvement of TP53 is perhaps the main difference between this group of 
tumours and the low-grade Ta, in fact, have been identified many different mutations of 
TP5314.  
In conclusion numerous deletions on chromosome arms (9q, 11p, 17p) characterize bladder 
carcinomas. There are also correlations between the degree of malignancy and specific 
deletions (3p, 17p). The stadium is associated with deletions of 3p, 17p , and with the altered 
expression of the gene RB (retinoblastoma), and vascular invasion correlates with the 17p 
deletion. Recent studies demonstrated that  in the literature p53/p21 alterations appear to play 
a prognostic predictor of recurrence and disease progression15although the results obtained so 
far are still controversial, and further studies are therefore needed. 
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Figure 5. Current genetic data suggest two major subtypes/pathways of bladder urothelial 
tumours. 
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1.6 SIGNS AND SYMPTOMS  
 
Bladder cancer characteristically causes blood (redness) in the urine. This blood in the urine 
may be visible to the naked eye (gross/macroscopic hematuria) or detectable only by 
microscope (microscopic hematuria)16. Hematuria is the most common symptom in bladder 
cancer. Other possible symptoms include pain during urination, frequent urination, or feeling 
the need to urinate without being able to do so. These signs and symptoms are not specific to 
bladder cancer, and are also caused by non-cancerous conditions, including prostate 
infections, over-active bladder and cystitis. There are many other cause of hematuria, such as 
bladder or ureteric stones, infection, kidney disease, kidney cancers and vascular 
malformations. 
1.7 PREVENTION 
 
A 2008 study commissioned by the World Health Organization concluded that "specific fruit 
and vegetables may act to reduce the risk of bladder cancer"9,17. Fruit and yellow-orange 
vegetables, particularly carrots and those containing selenium18, are probably associated with 
a moderately reduced risk of bladder cancer. Citrus fruits and cruciferous vegetables were 
also identified as having a possibly protective effect. However, an analysis of 47.909 men in 
the Health Professionals follow-up study showed little correlation between cancer reduction 
and high consumption of fruits and vegetables overall, or yellow or green leafy vegetables 
specifically, compared to the statistically significant reduction among those men who 
consumed large amounts of cruciferous vegetables. 
17 
 
Several studies have suggested that the bladder is one of the most responsive organs to 
induction of detoxification enzymes by extract. This was evident in human bladder cancer 
cells in vitro and in animal models in vivo. Sulforaphane and broccoli sprout extract were 
also observed to induce apoptosis and cell cycle arrest in human bladder cancer cells in vitro, 
an anti-cancer effect attributed to the sulforaphane potential in the sprouts19,20. 
1.8 DIAGNOSIS 
Many patients with a history, signs, and symptoms suspicious for bladder cancer are referred 
to a urologist or other physician trained in cystoscopy, a procedure in which a flexible tube 
bearing a camera is introduced into the bladder through the urethra. Suspicious lesions may 
be biopsied and sent for pathologic analysis. The gold standard for for the diagnosis of 
bladder cancer is biopsy obtained during cystoscopy. Sometimes it is an incidental finding 
during cystoscopy. Urine cytology can be obtained in voided urine or at the time of the 
cystoscopy ("bladder washing"). Cytology is not very sensitive especially for low grade and 
stage tumours (a negative result cannot reliably exclude bladder cancer)21(Table 1). The 
diagnosis of bladder cancer can also be done with a Hexvix/Cysview guided fluorescence 
cystoscopy (blue light cystoscopy, Photodynamic diagnosis), as an adjunct to conventional 
white-light cystoscopy. This procedure improves the detection of bladder cancer and reduces 
the rate of early tumour recurrence, compared with white light cystoscopy alone. Cysview 
cystoscopy detects more cancer and reduce recurrence. Cysview is marketed in Europe under 
the brand name Hexvix22. However, visual detection in any form listed above, is not 
sufficient for establishing pathological classification, cell type or the stage of the present 
tumour. A so-called cold cup biopsy during an ordinary cystoscopy (rigid or flexible) is not 
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sufficient for pathological staging. Hence, a visual detection needs to be followed by 
transurethral surgery. The procedure is called transurethral resection (TUR). Further, 
bimanual examination should be carried out before and after the TUR to assess whether there 
is a palpable mass or if the tumour is fixed ("tethered") to the pelvic wall. The pathological 
classification obtained by the TUR-procedure, is of fundamental importance for making the 
appropriate choice of ensuing treatment and/or follow-up routines23. 
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                   Table 1. Diagnostic accuracy of  cytology  in the different studies21.  
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1.9 TREATMENT 
 
The treatment of bladder cancer depends on how deep the tumour invades into the bladder 
wall. Superficial tumours (those not entering the muscle layer) can be "shaved off" using an 
electrocautery device attached to a cystoscope, which in that case is called a resectoscope. 
TUR serves primarily for pathological staging. In case of non-muscle invasive bladder cancer 
the TUR is in itself the treatment, but in case of muscle invasive cancer, the procedure is 
insufficient for final treatment24. Immunotherapy by intravesicular delivery of Bacillus 
Calmette–Guérin is also used to treat and prevent the recurrence of superficial tumours25. 
Bacillus Calmette–Guérin is a vaccine against tuberculosis that is prepared from attenuated 
(weakened) live bovine tuberculosis bacillus, Mycobacterium bovis, that has lost its 
virulence in humans. BCG immunotherapy is effective in up to 2/3 of the cases at this stage, 
and in randomized trials has been shown to be superior to standard chemotherapy26. The 
mechanism by which BCG prevents recurrence is unknown, but the presence of bacteria in 
the bladder may trigger a localized immune reaction which clears residual cancer cells. 
Instillations of chemotherapy, such as valrubicin (Valstar) into the bladder, can also be used 
to treat BCG-refractory CIS disease when cystectomy is not an option 27. The drug Urocidin 
is currently in Phase III of trials for this procedure 28. Patients whose tumours recurred after 
treatment with BCG are more difficult to treat. Many physicians recommend cystectomy for 
these patients (Figure 6). This recommendation is in accordance with the official guidelines 
of the European Association of Urologists (EAU)24 and the American Urological Association 
(AUA)29. However, many patients refuse to undergo this life changing operation, and prefer 
to try novel conservative treatment options before opting to this last radical resort. Device 
assisted chemotherapy is one group of novel technologies used to treat superficial bladder 
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cancer30. These technologies use different mechanisms to facilitate the absorption and action 
of a chemotherapy drug instilled directly into the bladder. Another technology uses an 
electrical current to enhance drug absorption31. Another technology, thermotherapy, uses 
radio-frequency energy to directly heat the bladder wall, which together with chemotherapy 
shows a synergistic effect, enhancing each other's capacity to kill tumour cells. This 
technology has been studied by different investigators32,33.                                               
Untreated, superficial tumours may gradually begin to infiltrate the muscular wall of the 
bladder. Tumours that infiltrate the bladder require more radical surgery where part or all of 
the bladder is removed (cystectomy) and the urinary stream is diverted into an isolated bowel 
loop (ileal conduit or urostomy). In some cases, skilled surgeons can create a substitute 
bladder (neobladder) from a segment of intestinal tissue, but this largely depends upon 
patient preference, age of patient, renal function, and the site of the disease. A combination 
of radiation and chemotherapy can also be used to treat invasive disease. It has not yet been 
determined how the effectiveness of this form of treatment compares to that of radical 
ablative surgery. Photodynamic diagnosis may improve surgical outcome on bladder 
cancer34. For muscle invasive urothelial urinary bladder cancer there are a number of 
treatment options. Gold standard is radical cystectomy as mentioned. In males this usually 
includes also the removal of the prostate and in females, ovaries, uterus and parts of the 
vagina. In order to address the problem of micrometastatic disease which in itself has 
implications on longtime survival, new treatment options are dearly needed. Micrometastatic 
dissemination is often not treatable with only major surgery and the concept of neoadjuvant 
chemotherapy has evolved.  
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Figure 6. Flow chart of the Bladder Cancer Treatment Guide. 
 
 
 
 
 
 
 
 
 
 
23 
 
2. NEW MOLECULAR NON INVASIVE APPROACHES 
 
2.1 TUMOUR MARKERS 
 
The availability of more accurate diagnostic and possibly non-invasive tests has been a major 
objective pursued intensively in recent years. An ideal diagnostic marker should have both a 
high sensitivity and specificity, and also be able to detect well-differentiated and early stage 
tumours. The method must also be simple, and sufficiently inexpensive to facilitate the 
analysis of a large number of urine samples in a reasonable amount of time. In recent years, 
several markers of diagnostic relevance have been identified and a number of reagents 
directed against molecular targets have been developed commercially21 (Table 2). The most 
intensively investigated are chromosome alterations detected by fluorescence in situ 
hybridization (FISH), urinary human complement factor H related protein (BTA stat and 
BTA TRAK), nuclear matrix protein (NMP22) and cytocheratin 8 and 18 fragments (UBC 
rapid, and UBC immunoradiometric assay, UBC ELISA). With regard to the most 
intensively investigated markers, consistent results have been obtained for FISH, with a 
sensitivity of approximately 80%, and a specificity between 90 and 100% in case-control 
studies. However, the test is expensive, cannot be performed in all laboratories, and accuracy 
strongly decreases when it is used for symptomatic patients. FISH requires specialized 
personnel to ensure a correct morphologic evaluation. Similar sensitivity and specificity have 
been reported for NMP22 in case control studies, albeit with lower accuracy, especially in 
terms of sensitivity in symptomatic patients. For all these molecular tests, sensitivity ranges 
from 40 to 100% in different case-control studies, and from 40 to 82% in symptomatic 
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patient series. Specificity also varies markedly, from 64 to 100% in the former, and from 65 
to 86% in the latter subgroups (Table 2) 21. 
Moreover, intra-assay variability is often higher than inter-assay variability, indicating a 
potential lack of standardization of technical aspects and pre-analytical phases. 
Indeed, specific protocols and standards often adopted by individual laboratories determine a 
wide range of results which are not easily comparable. 
 
                        Table 2. Diagnostic accuracy of different non-invasive assay. 
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2.2 THE ROLE OF TELOMERASE 
 
Among the markers most recently proposed to improve diagnostic accuracy, especially in 
terms of sensitivity, increasing attention has been focused on the role of the 
ribonucleoprotein, telomerase. This enzyme consists of three subunits: an RNA component 
(hTR), which acts as a template for DNA replication35, a telomerase associated protein 
(TP1)36 of as yet unknown function, and the telomerase reverse transcriptase (hTERT), which 
is responsible for catalytic activity37. Telomerase activity (TA) has been detected in almost 
all malignant cells and tissues, and only very occasionally in normal somatic cells38-40. The 
telomeric repeat amplification protocol assay (TRAP), a polymerase chain reaction (PCR) 
based method for detection of TA, has been available since 199438.The introduction of this 
method is an important milestone in telomerase research and has become the standard 
method for studying the diagnostic relevance of this enzyme (Table 3)39-43.  TA has also been 
determined qualitatively and quantitatively using modified TRAP assays, for example TRAP 
scintillation proximity assay, TRAP-ELISA, fluorescent TRAP assay, TRAP hybridization 
assay, and bioluminescence linked with TRAP. Other methods have focused on the detection 
of the telomerase subunits, hTR and hTERT, using the reverse transcriptase polymerase 
chain reaction (RT-PCR). Real-time PCR methods have also permitted a quantitative and 
reproducible determination of these subunits. 
Expression of the hTERT protein has also been analyzed by immunocytochemistry using 
anti-hTERT monoclonal 44,45 and polyclonal antibodies. 
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Table 3. Diagnostic accuracy of telomerase-based assays. 
 
 
 
2.2.1 TELOMERASE  EVALUATION  
 
2.2.1.1  ENZYMATIC ACTIVITY 
 
TRAP assay 
 
The detection of TA in bladder washing and voided urine has been investigated for its 
diagnostic potential. Since this technique detects TA, and not only the presence of the 
enzyme, viable cells are a prerequisite. In fact, a possible limitation of the TRAP assay is the 
potential vulnerability and inactivation of the enzyme by external factors. Bladder washings 
are obtained by mechanical irrigation of the empty urinary bladder using saline solution at 
physiological pH. However, in native urine, suspended tumour cells are exposed to 
destructive substances such as proteases, urea, salts and, usually, acid pH, for variable times. 
All of these factors may lead to early inactivation or degradation of the enzyme that could 
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explain the lack of reproducibility of results among the different studies. Moreover, bladder 
washings are obtained through the use of a catheter or cystoscope, which are both invasive 
instruments. For this reason, voided urine has been the most widely used biological sample 
for the TRAP assay. The first reported TRAP assay studies were based on qualitative, and 
thereafter with semi-quantitative TA determinations46. To obtain more accurate and reliable  
results, a quantitative TRAP assay was developed in bladder washings and voided urine, 
based on exponential amplification of the primer-telomeric repeats generated in the 
telomerase reaction41,47-50. Several case-control studies have also confirmed that this test is 
more accurate in males than females41, with a higher specificity in younger than older 
individuals42.  A recent study by the same authors suggested that these results could be due to 
the presence of inflammatory cells, which are almost always positive to telomerase21. 
Furthermore, the diagnostic accuracy of TA was not related to the tumour stage or grade, and 
was as high in both early stage and low grade tumours, including in situ carcinomas41, in 
contrast to what has been reported by other authors51. However, before introducing this test 
in routine clinical practice, in combination with, or as an alternative to invasive cytoscopy, its 
potential, in terms of sensitivity and specificity, must be further investigated and defined in a 
consecutive series of symptomatic individuals52. 
 
2.2.1.2  EXPRESSION OF hTR AND hTERT 
RT-PCR 
It has been shown that transcriptional regulation of the catalytic component of the telomerase 
complex is a major determinant in the control of TA41,42. Meanwhile, hTR seems to be 
ubiquitously expressed in most cells independent21 of enzyme activity. Studies have pointed 
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out that high hTERT mRNA expression is associated with malignancy in many tumour 
histotypes, and has shown great potential for early cancer detection in body fluids5. Indeed, 
the expression of hTERT and hTR mRNA, both in tissues53 and in voided urine samples, 
seems to correlate positively with tumour stage and grade, even if these data have not, as yet, 
been confirmed54. Moreover, a good concordance has been shown between mRNA of both 
telomerase subunits and telomerase activity54,55. 
 
IMMUNOHISTOCHEMISTRY 
Many studies have shown that the TRAP assay does indeed have some drawbacks, the most 
important being the rate of false positives due to the presence of inflammatory non-tumour 
cells in voided urine and bladder washings13,21. It is therefore important to carry out a 
morphological analysis to identify the true nature of urothelial telomerase expressing cells 
(Figure 7) and to unmask any false TRAP positives (Figure 8). The availability of both 
monoclonal (Mab tel 3 36-10 DIESSE Diagnostica Senese Italy, commercialized by the 
Alexis Corporation, Lausanne, Switzerland; NCL hTERT Novocastra, Newcastle- upon Tyne 
UK) and polyclonal antibodies (TERT H-231: sc-7212, Santa Cruz Biotechnology Inc, Santa 
Cruz, CA, USA; hTERT EST21A Alpha Diagnostic  International, San Antonio, TX), able to 
detect hTERT protein expression, has opened up the possibility of studying the different cell 
components. The diagnostic accuracy of the TRAP assay could be improved by considering 
the percentage of non-tumour hTERT-expressing cells in the same urine sample. However, it 
still needs to be demonstrated that the two markers are equivalent. In fact, there is evidence 
that some tissues may be positive for hTERT mRNA, but not for TA. 
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Figure 7: Immunoreactivity of bladder tumour cells to Mab anti-hTERT tel 3 36-10 Diesse21. 
 
 
Figure 8: Immunoreactivity of inflammatory cells to Mab anti-hTERT tel 3 36-10 Diesse,21. 
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2.3 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 
Bladder cancer progression is accompanied by increased chromosomal instability and 
aneuploidy56. Cytogenetic studies reveal frequent alterations of a variety of chromosomes 
including chromosomes 1, 3, 7, 9, 17, and others56. These chromosomal alterations can be 
detected with fluorescence in situ hybridization (FISH)57,58. FISH utilizes fluorescently 
labeled DNA probes to chromosomal centromeres or unique loci to detect cells with 
numerical or structural abnormalities indicative of malignancy. Studies have demonstrated 
that FISH, using the UroVysion® probe set, has similar specificity to and better sensitivity 
than routine cytology for detecting bladder cancer in urine. Vysis UroVysion® is a molecular 
cytology test that detects aneuploidy of chromosomes 3, 7, and 17 and deletion of the 9p21 
locus via fluorescence in situ hybridization (FISH) in urine specimens. Presently, as 
approved by the US Food and Drug Administration (FDA), the UroVysion® assay is simply 
reported qualitatively as 'positive' or 'negative' for abnormality. However, recent studies 
indicate that assessing FISH quantitatively (i.e., pattern of chromosomal abnormality and 
percentage of abnormal cells) may help better predict which patients will recur and progress 
to muscle invasive disease59. Researchers have found that increased chromosomal instability 
and aneuploidy, such as that detected by the Vysis UroVysion test, are characteristic of 
bladder tumour progression. Due to its high specificity (~96%) and increased sensitivity 
(Table 2), the Vysis UroVysion test is useful for early detection of bladder cancer recurrence 
when used in conjunction with cystoscopy. When the Vysis UroVysion test is positive and 
cystoscopy is negative, cancer recurs on average 4 months earlier than when both tests are 
negative; thus, a positive Vysis UroVysion test may indicate a need for increased 
surveillance in these cases.  
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Given this quantitative information, patients with an anticipated uneventful clinical course 
and/or recurrent low-grade papillary tumours can be distinguished from those who are at a 
high risk of tumour progression. Accordingly, surveillance strategies could be tailored for 
individual patients on the basis of the biological properties of their disease.  
2.4 DNA INTEGRITY 
 
The presence of circulating cell-free DNA in plasma or serum has been reported to be a 
suitable marker of prostate 60 and lung cancer 61,62  but few studies have focused on the 
potential of urine cell-free (UCF) DNA to detect bladder cancer 63-65. It is very important to 
assess whether DNA integrity is able to distinguish bladder cancer patients from from 
healthy individuals or from those with benign urologic disease. This hypothesis is based on 
the well-known fact that DNA from normal cells in apoptosis is highly fragmented, while 
DNA from necrotic cancer cells maintains its integrity 66.  It has been demonstrated that urine 
cell-free DNA fragments longer than 250 bp of 3 biomarkers frequently amplified in bladder 
cancer are: c-Myc (8q24.21), HER2 (17q12.1), and BCAS1 (20q13.2) 67,69.    
 
 
 
 
 
 
 
 
 
32 
 
 
3. AIM OF THE STUDY 
 
RATIONAL AND  INTRODUCTION FOR THE EXPERIMENTAL WORK 
 
The early diagnosis of urogenital tumours has a strong impact on the probabilities of 
recovery and survival of patients affected with these pathologies. Therefore the identification 
of accurate and sensitive tumour markers able to diagnose these neoplasms early is essential 
for non invasive diagnostic approaches. 
Cystoscopy is the standard approach to the diagnostic work-up of urinary symptoms. It has 
high sensitivity and specificity for papillary tumours of the bladder but suboptimal sensitivity 
and specificity for flat carcinomas. It is also expensive and may cause discomfort and 
complications. Urine cytology, in contrast, has the advantage of being a noninvasive test with 
high specificity but suffers from low sensitivity possibly due to the low number of exfoliated 
cells in urine, and particularly in low-grade and early-stage tumours. Numerous new 
noninvasive tests have been proposed but up to now there are no diagnostic markers in 
clinical practice for non-invasive urogenital cancers that are sufficiently accurate in terms of 
sensitivity and specificity. For bladder cancer, there are numerous studies aimed at 
identifying new molecular markers in urine of diagnostic relevance, but, so far, none of these 
have an optimal accuracy (both in terms of sensitivity and specificity).  
Important results on the diagnostic relevance of urine telomerase have been published by our 
group in pilot and confirmatory case-control studies (Table 4) but its role in symptomatic 
individuals is not well known.  
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In particular, the objective of the first study, was to determine whether combining cytology 
and the TRAP assay for the detection of TA with FISH analysis improves the diagnostic 
performance of cytology alone in patients with urological symptoms consecutively enrolled 
(symptomatic patients), which represent the target subset for the activation of screening 
programs70.  
 It would also be interesting to consider other approaches to see whether diagnostic accuracy 
and cost-effectiveness can be further improved. The presence of circulating cell-free DNA in 
plasma or serum has been reported to be a suitable marker of prostate 60 and lung cancer61,62 
but few studies have focused on the potential of urine cell-free (UCF) DNA to detect bladder 
cancer63-65.   
In the second study, the capability of DNA integrity in urine supernatant in distinguishing 
cancer patients from healthy individuals or from those with benign urologic diseases was 
assessed. This hypothesis is based on the well-known fact that DNA from normal cells in 
apoptosis is highly fragmented, while DNA from necrotic cancer cells maintains its 
integrity66. To this end urine cell-free DNA fragments longer than 250 bp of 3 biomarkers 
frequently amplified in bladder cancer: c-Myc (8q24.21), HER2 (17q12.1), and BCAS1 
(20q13.2)67,69 were analyzed. 
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                                  Table 4. Studies published  by our  research group on telomerase. 
 
 
Sens.: Sensitivity 
Spec.: Specificity 
 N° tot 
Cases 
 
N° Cases Males Females Global Series 
   
Males     Females 
%          % 
Sens.    Spec. 
%           % 
Sens.  Spec. 
%            % 
Sens.      Spec. 
Neoplasia  
Sanchini 
2004 
200 140           60 93          90 86         71 92          81 
JAMA 
Sanchini 
2005 
218 218             - 90          88 -           - 90          88 
J UROL 
Bravaccini 
2007 
212 -             212 -             - 87         66 87          66 
IJBM 
Casadio  
2009 
515 465           50 88          70 79         62 87          70 
IJU (review) 
Bravaccini 
2009 
- - - - - 
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4. MATERIALS AND METHODS 
 
4.1 Case series 
First study  
The following diagnostic procedures were compared for sensitivity and specificity with 
cytology alone: TRAP assay alone; cytology and TRAP assay in parallel, with subjects 
positive at either test being classified as positive; cytology in parallel with the in-series 
combination of TRAP assay and FISH analysis, with subjects positive at cytology and those 
positive at both TRAP and FISH being classified as positive; and the in-series combination of 
TRAP and FISH, with subjects positive at both tests being classified as positive. The use of 
TRAP assay alone was aimed to confirm that this technique is more sensitive than 
cytology41,42. Combining cytology and TRAP in parallel was designed to increase the 
sensitivity of cytology. The use of cytology in parallel with the in-series combination of 
TRAP assay and FISH analysis reflected the assumptions that cytology is fairly specific and 
does not need in-series testing; the specificity of TRAP may be improved with an in-series 
combination with the FISH analysis71 and thus, cytology in parallel with the TRAP–FISH 
sequence could maximize sensitivity while retaining an acceptable specificity. Finally, the in-
series combination of TRAP and FISH was expected to produce the greatest specificity. All 
study patients were submitted to cytology testing and TRAP assay. TRAP-positive patients 
underwent FISH analysis. All patients underwent cystoscopy, and biopsy if appropriate. 
cystoscopy (and biopsy, if any) was considered the gold standard. 
Patients who were seen in the Urology Department of the Morgagni-Pierantoni Hospital in 
Forlı` (the only public general hospital in a catchment area of about 80.000 people in 
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northern Italy)  between January 2007 and June 2008, presented with urinary tract symptoms,  
reported no history of bladder cancer, underwent cystoscopy, and had conclusive results for 
cytology, TRAP assay, and FISH analysis were eligible for the study. 
Three hundred consecutive patients were enrolled. Of the 120 TRAP positive patients 
submitted to FISH analysis, 11 (9%) (9 with cancer) had inconclusive results and were 
excluded from analysis, leaving 289 assessable subjects (238 men, 51 women; median age 70 
years; range 28–92 years). 
One hundred thirteen patients reported micro/macrohematuria, and 176 (61%) irritative 
symptoms alone. Seventy-four patients (62 men, 12 women; median age 74 years; range 47–
92 years) were diagnosed with bladder cancer, 39(53%) of whom had micro/macrohematuria. 
Urine test was carried out blindly to histological diagnosis. Eighty patients underwent biopsy. 
All cases of bladder cancer were histologically confirmed. In accordance with the 2004 
World Health Organization guidelines, tumour samples were classified as high or low grade. 
Patients diagnosed with benign disease were followed-up for at least one year using clinical 
data from hospital records, and their status was confirmed. There were no losses to follow-
up. The local ethics committee approved the study protocol and all participants provided 
written informed consent to take part in the study. 
Second study  
A total of 129 individuals (51 bladder cancer patients at first diagnosis, 46 symptomatic 
patients with benign urogenital  diseases, and 32 healthy individuals; Table 5) were recruited 
from the Urology Department of Morgagni-Pierantoni Hospital (Forlì). All participants 
provided written informed consent to take part in the study and the local Ethics Committee 
reviewed and approved the study protocol. 
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Patients with bladder cancer or benign urogenital diseases were submitted to cystoscopy, 
after which those with malignancies or suspicious lesions underwent transurethral resection 
of the bladder (TURB). The final diagnosis of cancer was based on histologic results from 
TURB. Tumour type and differentiation were based on 2004 World Health Organization 
criteria. Symptomatic patients were diagnosed with different benign diseases: prostatic 
adenomas or benign hyperplasia (14 cases), kidney stones (3), cysts (13), lithiasis (3), 
prostatitis (3), bladder edema (1), and bladder diverticula (1). Eight patients did not have any 
disease. 
Twenty-eight percent of symptomatic patients had hematuria at the time of urine collection. 
The control group of healthy individuals with no previous urogenital diseases or cancer was 
matched to patients by gender and age. UCF DNA integrity analysis was performed blindly 
in all individuals and was evaluable for the entire case series. Cytologic results were 
available for 76 patients (41 cancer cases and 35 symptomatic individuals). 
Table 5. Case series. 
 
 
4.2 Urine collection  
First study 
Urine samples were collected immediately before cystoscopy. For the TRAP assay, 3 ml of 
urine was used and cells were pelleted by centrifugation (850 g for 10 min at 4°C) within 3 h 
of urine collection, washed once in phosphate-buffered saline (1X), resedimented by 
centrifugation (2300 g for 5 min at room temperature), and stored at -80°C until use 
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(maximum of 12 months). Pelleted cells were then resuspended in 200 µl of lysis reagent and 
left on ice for 30 min. Cell lysates were centrifuged at  10.000 g for 20 min at 4°C and the 
supernatant was stored at -20°C. The results of the cytological evaluation (Pathology 
Department, Morgagni-Pierantoni Hospital, Forlì) were reported in a descriptive manner and 
were classified as negative and positive by laboratory biologists at our institution. Dubious  
findings were considered a positive result. 
For the FISH test, in accordance with the manufacturer’s instructions57 (UroVysionTM; 
Abbott/Vysis, Downers Grove, IL), at least 33 ml of urine was used and cells were collected 
by cytospin centrifugation (1200 g for 5 min). Cells were fixed in Carnoy’s fixative for 20 
min and dehydrated for 2 min each in ethanol scalar dilutions (70%, 85%, 100%), after which 
the slides were heated at 45°C–50°C for 2–3 min and stored at 4°C for a maximum of 1 
month. 
 
Second study 
First morning voided urine samples for UCF DNA analysis were collected from healthy 
individuals about 1 week after cytologic examination, and from symptomatic individuals and 
bladder cancer patients immediately before cystoscopy. All patients and controls were 
instructed to give clean-catch urine samples, maintained at 4°C for a maximum of 3 hours. 
Thirty milliliter aliquots of urine were centrifuged at 850 g for 10 minutes and the 
supernatants were transferred to cryovials and immediately stored at -80°C until use. 
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First study 
4.3 TRAP assay 
Urine sample aliquots containing 1 µg of protein lysate were used for the TRAP assay. As 
previously41,42, telomerase products were evaluated on fluorescent electropherograms and the 
area underlying the different peaks was calculated. An internal telomerase assay standard 
(ITAS; 25 attograms) amplified by the same two primers used for TA determination was 
included in the TRAP buffer to obtain a semiquantitative evaluation. Protein concentrations 
corresponding to 10, 30, 100, 300, 1000, and 3000 cells of a human bladder cancer cell line 
(MCR) were analyzed in each assay and used as the reference curve. The areas of each 
sample were also normalized to the 150-base pair ITAS peak to obtain quantitative TA 
evaluations. The relative TA per cell for each sample is expressed as the percentage of the 
ratio of TRAP ladder/ITAS per cell versus the value of MCR and expressed in arbitrary 
enzymatic units. 
TRAP assay was carried out on the entire case series (100% feasibility). All experiments 
were carried out blindly in duplicate and, when variations were >15% (observed in  about 
10% of cases), a third analysis was carried out. TA was expressed as a continuous variable. 
 
4.4 FISH analysis 
Hybridization was carried out according to the manufacturer’s instructions57 (UroVysion; 
Abbott/Vysis). The probe mixture consisted of fluorescently labeled probes targeted to the 
pericentromeric regions of chromosomes 3 (CEP3 Spectrum Red), 7 (CEP7 Spectrum 
Green), and 17 (CEP17 Spectrum Aqua), and to band 9p21 locus (LSI 9p21 Spectrum Gold) 
over each target area (Figure 9); 3 µl of the probe mix solution was applied. Target DNA and 
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FISH probes were co-denatured at 73°C for 2 min using a commercial hybridization system 
(HYBrite; Abbott/Vysis) and subsequently incubated at 39°C overnight. 4’,6-diamidino-2-
phenylindole was used for counterstaining and cells were viewed using a fluorescent 
microscope (Axioscope; Zeiss, Göttingen, Germany). All slides were scanned and the 
number of CEP3, CEP7, CEP17, and 9p21 signals in the cells was determined. The presence 
of at least 25 cells per slide was required to consider a sample as evaluable, and two signals 
for each chromosome were indispensable to consider a cell as normal. The presence of four 
or more cells with gains for two or more chromosomes (3, 7, or 17) in the same cell, or 12 
cells or more with zero 9p21 signals was the criterion to consider a specimen as positive. 
Slides were evaluated independently by two experts blinded to the patient’s history and 
histological findings. 
 
Figure 9. Correspondence between fluorescent signals and chromosome. 
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Second study 
4.5 UCF DNA analysis 
DNA was extracted and purified from 2 ml of supernatant by Qiamp DNA minikit (Qiagen, 
Milan, Italy) according to the manufacturer’s instructions. At the same time, DNA was 
extracted from a human bladder cancer cell line (MCR) using the same minikit. DNA was 
quantified by spectrophotometry (NanoDrop ND-1000; Celbio, Milan, Italy). Real Time PCR 
reactions were carried out by Rotor Gene 6000 detection system (Corbett Research, St. 
Neots, UK) using IQ SYBR Green (Bio-Rad, Milan, Italy). Sequences longer than 250 bp, 
corresponding to 3 oncogenes were analyzed: c-Myc (locus 8q24 and 21,amplification 
product 264 bp), BCAS1 (locus 20q.13.2, amplification product 266 bp), HER2 (locus 17q12 
and 1, amplification product 295 bp). A short 125 bp fragment of STOX1 (locus 10q21 and 3) 
was analyzed to check for potential PCR inhibition. Primer sequences were as follows:  
c-Myc fw TGGAGTAGGGACCGCATATC, rev ACCCAACACCACGTCCTAAC; 
BCAS1 fw GGGTCAGAGCTTCCTGTGAG,rev CGTTGTCCTGAAACAGAGCA; 
HER2 fw CCAGGGTGTTCCTCAGTTGT, rev TCAGTATGGCCTCACCCTTC;  
STOX1 fw GAAAACAGGGCAGCAAGAAG, rev CAGACAGCATGGAGGTGAGA. 
PCR conditions for the oncogenes were as follows: 95°C for 3 minutes, then 45 cycles at 
94°C for 40 seconds, 56°C for 40 seconds, and 72°C for 1 minute. PCR conditions for the 
short STOX1 sequence were as follows: 95°C for 90 seconds, then 45 cycles at 94°C for 40 
seconds,  and 54°C for 1 minute. All real time PCR reactions were performed in duplicate on 
10 ng of each UCF DNA sample. 
Various amounts of DNA from the MCR cell line (0.01, 0.1, 1, 5, 10 and 20 ng) were also 
analyzed to construct a standard curve. The UCF DNA value for each sample was obtained 
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by Rotor Gene 6000 detection system software using standard curve interpolation. The 
analysis was repeated if the difference between duplicate samples was greater than 1 cycle 
threshold. The final UCF DNA integrity value was obtained by the sum of the 3 oncogene 
values. Real time experiments were performed independently in duplicate on the same 8 
samples to test assay imprecision. The coefficients of variation (CV) were then calculated for 
c-Myc, HER2, BCAS, and STOX1. 
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5. STATISTICAL ANALYSIS 
 
First study 
The study end points were sensitivity (the proportion of cancer patients who were correctly 
identified by the test or procedures) and specificity (the proportion of healthy individuals 
who were correctly identified)72, with their 95% confidence intervals (CIs). 
The negative and positive predictive values and overall accuracy are not presented for 
reasons of brevity. However, the reference diagnosis and the results of all tests are cross-
tabulated to allow the reader to calculate these measures (Table 6). 
 
 
Table 6.  Distribution of patients according to reference diagnosis, cytology, telomeric repeat 
amplification protocol (TRAP) assay, and FISH analysis. 
 
 
 
 
a. Diagnosis based on cystoscopy and biopsy (if deemed appropriate). 
b. In accordance with the study protocol, FISH analysis was carried out only if the result of the TRAP assay was 
positive. 
 
Subgroup analyses were carried out to determine whether the results differed by patient and 
tumour characteristics. Urinary bleeding was considered to encompass microhematuria and 
macrohematuria. 
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The McNemar test was used to compare sensitivity and specificity rates. A P value of <0.05 
was considered significant. To quantify the difference between two rates, their ratio and 95% 
CIs were calculated73.To compare changes in sensitivity or specificity, the ratio of the above 
ratios was calculated70,73. 
Second study 
The relationship between UCF DNA integrity value and the different subgroups (healthy 
individuals, symptomatic individuals, and cancer patients) was analyzed using a 
nonparametric ranking statistic test. The most discriminating cutoff values between healthy 
individuals, symptomatic individuals, and cancer patients were identified using receiver 
operating characteristic (ROC) curve analysis. The true positive rates (sensitivity) were 
plotted against the false positive rates (1 specificity) for all classification points. Accuracy 
was measured by the area under the ROC curve (AUC), which represents an average 
probability of correctly classifying a case chosen at random. Study endpoints were sensitivity 
(the proportion of cancer patients who were correctly identified by the test or procedures) and 
specificity (the proportion of healthy individuals who were correctly identified), with their 
95% confidence intervals (CIs)72. Spearman’s nonparametric test was used to evaluate the 
correlation between total DNA value and DNA integrity. 
The McNemar test was used to compare sensitivity and specificity rates. P values < 0.05 
were considered statistically significant. Statistical analyses were performed using SPSS 
statistical software (ver. 12.0; SPSS GmbH Software). 
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6. RESULTS 
 
First study 
Total sensitivity and specificity 
Of the 300 enrolled patients, 120 were TRAP positive and FISH was performed as second 
level approach. FISH had inconclusive results on 11 cases (Figure 10). 
The TRAP assay as well as the combination of cytology and TRAP and of cytology, TRAP, 
and FISH were more sensitive and less specific than cytology (Table 7). The combination of 
cytology, TRAP, and FISH provided the best trade-off between sensitivity and specificity. It 
showed the same high level of sensitivity as the combination of cytology and TRAP in 
parallel (0.78) and a more moderate decrease in specificity (0.78 versus 0.60, P = 0.000). It 
also had greater sensitivity than the TRAP assay alone (0.78 versus 0.66, P = 0.004) and a 
comparable level of specificity (0.78 versus 0.72, P = 0.136). 
The combination of TRAP and FISH exhibited the highest level of specificity, with 
sensitivity almost identical to that of TRAP alone. 
The figures 11 and 12 represent  urothelial cells with chromosomal aneuploidy and normal 
cells form healthy individuals on fluorescent microscope (Zeiss Germany). 
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                                              Figure 10. Flow chart of the first study. 
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Table 7. Total sensitivity and specificity of the diagnostic procedures. 
 
 
 
 
 
                       a. For comparison with cytology alone (McNemar test). 
                       b. Cytology and TRAP in parallel. Subjects positive at either test were classified as positive 
                       c. Cytology in parallel with the in-series combination of TRAP and FISH. 
                       Subjects positive at cytology plus those positive at both TRAP and FISH were  
                       classified as positive. 
                       d. TRAP and FISH in series. Subjects positive at both tests were classified as positive. 
                       CI, confidence interval; TRAP, telomeric repeat amplification protocol. 
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Figure 11. Urothelial Cells (big magnification) of patients with chromosomal aneuploidy  
and  normal cells of healthy individuals.  
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Figure 12. a) invasive squamous cell carcinoma of the bladder (hematoxylin-eosin).  
b) d) urothelial tumour cells of patients FISH positive (note the loss of the gold signal 
corresponding to the locus 9p21 and numerous aneuploidies of chromosomes 3,7,17).  
c) urothelial cell tumour of patient FISH positive (at higher magnification) with aneuploidy 
of chromosome 7 and chromosome 17 (note 6 copies of the spots green and blue). 
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Sensitivity and specificity according to patient characteristics 
Subsequent analyses were focused on the combinations of tests that included both TRAP and 
FISH. The relative increase in sensitivity associated with the combination of cytology, 
TRAP, and FISH was greater among patients with irritative symptoms because non-bleeding 
cancers were especially difficult to detect by cytology alone (Table 8). A 3.57-fold increase 
(from 0.20 to 0.71) in sensitivity was observed among patients with irritative symptoms, and 
a 1.50-fold (from 0.56 to 0.85) increase among patients who reported bleeding. Conversely, 
the relative loss in specificity was virtually the same in both groups, i.e. 0.95 (from 0.88 to 
0.84) among patients with irritative symptoms versus 0.93 (from 0.73 to 0.68) among those 
who experienced bleeding. 
The same pattern of improvement in sensitivity in relation to patient clinical status was 
observed for the combination of TRAP and FISH, albeit at lower absolute levels. This 
combination brought about an increase in specificity of comparable magnitude among 
patients in both groups. 
Changes in sensitivity and specificity were also compared between age (<70 versus >70 
years) and gender groups, with nonsignificant differences observed. 
 
 
 
 
 
 
 
51 
 
Table 8. Sensitivity and specificity of cytology alone and of combinations of cytology, 
telomeric repeat amplification protocol (TRAP) assay, and FISH analysis in patients 
reporting irritative symptoms alone and those with urinary bleeding. 
 
 
 
 
 
a.  Including microhematuria and macrohematuria. 
b. Cytology in parallel with the in-series combination of TRAP and FISH. Subjects positive at cytology plus 
those positive at both TRAP and FISH were classified as positive. 
c. For comparison with cytology alone (McNemar test). 
d. TRAP and FISH in series. Subjects positive at both tests were classified as positive. 
CI, confidence interval. 
 
Sensitivity according to tumour characteristics 
Table 9 shows the relation between tumour grade and stage and the sensitivity increase 
obtained using the two test combinations above. Since the sensitivity of cytology was greater 
for high-grade cancers, the gain obtained by combining cytology with TRAP and FISH was 
higher among low-grade cancers (ratio 2.47; 95 CI 1.38–4.53). There was also a significant 
increase in sensitivity among early-stage cancers, which was not observed among late-stage 
cancers. The relative sensitivity performance of the combination of TRAP and FISH 
followed a similar pattern. 
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Table 9. Sensitivity of cytology alone and of combinations of cytology, telomeric repeat 
amplification protocol (TRAP) assay, and FISH analysis according to tumour grade and 
stage. 
 
 
 
 
Tumour grade was unknown for 4 of the 74 cancers in the case series, and tumour stage for one. 
a. Cytology in parallel with the in-series combination of TRAP and FISH. Subjects positive at cytology plus 
those positive at both TRAP and FISH were classified as positive. 
b. For comparison with cytology alone (McNemar test). 
c. TRAP and FISH in series. Subjects positive at both tests were classified as positive. 
CI, confidence interval. 
 
 
Second study 
Total free DNA was quantifiable by spectrophotometry, showing a median value of 6 ng/µl 
(range 2–138 ng/µl).UCF DNA integrity analysis was feasible and results were evaluable for 
all 129 individuals. The 125 bp STOX1 sequence was amplified in all samples, excluding the 
presence of PCR inhibitors. CVs were calculated, considering 2 measurements of each gene 
in a series of 8 samples, to test the interim imprecision of each assay. CVs were <0.12 for 
HER2, BCAS1, and STOX1, and <0.23 for c-Myc. No significant correlation was found 
between total free DNA and DNA integrity, thus suggesting that they are independent 
variables. Median values of UCF DNA integrity were significantly different in the 
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subgroups; the value was significantly (P< 0.0001) lower (0.004 ng/µl, range 0–1.883) in 
healthy individuals, more than 3-fold higher in symptomatic individuals (0.014 ng/µl, range 
0–0.864), and about 40-fold higher (0.15 ng/µl, range 0–4.460) in cancer patients  
(P< 0.0001). The AUC for UCF DNA integrity was 0.834 (95% CI 0.739–0.930) for cancer 
patients and healthy individuals, and 0.796 (95% CI 0.707– 0.885) for cancer patients and 
symptomatic individuals (Figure 13 and Figure 14). Analysis of sensitivity and specificity at 
different UCF DNA integrity cutoff values (0.04–0.14 ng/µl) showed a sensitivity ranging 
from 0.78 (95% CI 0.67– 0.89) to 0.53(0.39–0.67); specificity varied from 0.81 (95% CI 
0.67–0.95) to 0.91 (95% CI 0.81–1.00) in healthy individuals and from 0.63 (95% CI 0.49–
0.77) to 0.87 (95% CI 0.77– 0.97) in symptomatic patients   (Table 10). The best cutoff value 
was 0.1 ng/µl, providing the best trade-off between loss in sensitivity (0.73, 95% CI 0.61– 
0.85) and gain in specificity in both healthy individuals (0.84, 95% CI 0.71– 0.97) and 
symptomatic patients (0.83, 95% CI 0.72–0.94). A comparison of diagnostic performance 
between conventional cytology and UCF DNA integrity showed an increase in sensitivity 
from 0.53 (95% CI 0.35–0.71) to 0.70 (95% CI 0.62– 0.68) (P= 0.132), while specificity was 
slightly but not significantly reduced from 0.92 (95% CI 0.81–1.03) to 0.75 (95% CI 0.72– 
0.94) (P = 0.102) (Table 11). In a breakdown analysis of the difference in clinical pathologic 
subgroups, we observed an improved performance of UCF DNA integrity compared with 
that of cytology, more evident in males and independent of age. More importantly, sensitivity 
of  UCF DNA integrity increased for low grade tumours, from 0.15 (0–0.34) to 0.72 (0.53– 
0.91) (P=0.008), and for early stage Ta-T1 tumours, from 0.50 (0.30–070) to 0.72 (0.57– 
0.87) (P=0.058). There were too few patients with advanced tumours to permit such analysis. 
Specificity of UCF DNA integrity did not vary significantly with respect to cytology as a 
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function of gender, age, or any other clinical pathologic variables. To improve diagnostic 
performance, we constructed a flow diagram for a combined analysis of cytology and UCF 
DNA integrity (Figure 15). In the diagram we assumed that all cytology-positive individuals 
would not be subjected to further diagnostic evaluations and would therefore be considered 
as “positives.” Conversely, all individuals with dubious or negative cytology would be 
submitted to UCF DNA integrity analysis. With this combined analysis, we obtained 0.81 
sensitivity (95% CI 0.69–0.93), higher than that obtained with cytology (0.53) or UCF DNA 
integrity alone (0.73), and 0.77 specificity (95% CI 0.63– 0.91).To verify the role of each 
single gene in determining test accuracy, we also performed ROC curve analysis for each 
gene and obtained the following AUCs: 0.762 for c-Myc, 0.861 for BCAS1, and 0.757 for 
HER2. In symptomatic patients vs. cancer patients, AUCs were as follows: 0.763 for c-Myc, 
0.764 for BCAS1, and 0.708 for HER2. c-Myc and HER2 amplification in a subgroup of 36 
patients was also analyzed. FISH analysis showed a high correlation between the quantity of 
urinary DNA fragments and amplification in tissue for HER2 gene (P= 0.004), but no 
correlation for c-Myc (P = 0.140) (data not shown). As far as we know there is no 
commercially available probe for FISH analysis of BCAS1; an immunohistochemical 
approach which highlighted high expression of the gene in all tumour samples, confirming 
the potential role of this marker in bladder carcinogenesis was used. 
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Figure 13. ROC curve of UCF DNA integrity for cancer patients and healthy individuals. 
 
Figure 14. ROC curve of UCF DNA integrity for cancer patients and symptomatic patients. 
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Table 10. Sensitivity and specificity of different cutoffs of UCF DNA integrity in detecting 
bladder cancer. 
 
 
 
 
Table 11. Sensitivity and specificity of cytology and UCF DNA integrity in detecting bladder 
cancer. 
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 Figure 15. Flow diagram of sequential cytology and UCF DNA analysis. 
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7. DISCUSSION 
 
First study 
The rationale for this study was the recognized need to improve the performance of urine 
cytology in the diagnosis of bladder cancer. Using a multimodal approach, we combined 
cytology with TRAP assay and FISH analysis on the assumption that while using tests in 
parallel increases sensitivity but at the expense of specificity, an in-series combination results 
in the opposite. The sensitivity of cytology and TRAP assay in parallel was greater than that 
of cytology alone. As expected, however, this diagnostic algorithm brought about a marked 
loss in specificity. We thus designed a mixed procedure including cytology in parallel with 
the in-series combination of TRAP assay and FISH analysis, which provided the best trade-
off  between increase in sensitivity and loss in specificity. The increase in sensitivity was 
twofold, whereas specificity decreased only marginally. 
Two essential findings suggested that TRAP assay and FISH analysis may play a role in the 
diagnosis of bladder cancer. First, it rarely happens that carrying out two tests in series 
improves specificity while leaving unchanged sensitivity. This was the case for the TRAP 
assay and the FISH analysis. All cancer patients with negative cytology who were TRAP 
positive (n = 29) were also FISH positive (Table 6), which means that the FISH analysis is an 
ideal adjunct to the TRAP assay. The TRAP assay has the basic function of increasing the 
sensitivity of cytology41,42,52  and the FISH analysis decreases the false-positive TRAP results 
without missing any cancer. 
Secondly, we found that the above combination led to a greater increase in sensitivity among 
patients with irritative symptoms versus those reporting urinary bleeding, and among low-
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grade and early-stage cancers. In other words, the combination of cytology, TRAP assay, and 
FISH analysis had a greater impact on results in those conditions in which the sensitivity of 
cytology was lower. 
The ability of the FISH analysis to complement the TRAP assay was also evident from the 
results of their in-series combination without cytology, which reached a specificity as high as 
0.93. Furthermore, as all but one of the 49 TRAP-positive cancer patients were also FISH 
positive, the sensitivity of the combination remained virtually the same as that of TRAP 
alone (0.65 versus 0.66). 
Some methodological issues in this study need to be addressed. First, we excluded 11 
patients with inconclusive FISH analysis. As such results do not modify the result of the 
basic test (TRAP), patients with inconclusive FISH data could theoretically be considered as 
positive at the combination of cytology, TRAP assay, and FISH analysis. In this way, 
however, the rate of patients with inconclusive FISH analysis would become a direct 
determinant of sensitivity and an inverse determinant of specificity. To overcome this bias, 
we evaluated only those patients with valid results. 
Secondly, it is worthy of note that the specificity of routine cytology in this study was lower 
than expected. We can exclude that there were patients reported to have benign bladder 
disease who were subsequently diagnosed with cancer. The status of al of such patients was 
checked and confirmed after at least 1 year of follow-up. Low cytology specificity was most 
likely due to dubious results being reclassified as positive. Suspect cytology in Italian 
patients with urinary bladder symptoms, albeit poorly predictive of cancer, is generally taken 
seriously from a clinical point of view. 
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The study design was not suitable for drawing conclusions on the potential relevance of the 
FISH analysis as a basic diagnostic test for bladder cancer. This technique is very expensive, 
especially if both direct and indirect costs are taken into account. Thus, cost–utility 
considerations would seem to limit, a priori, its routine use for the characterization of the 
disease. Having said that, data presented in Table 1 are of interest on theoretical grounds. 
FISH analysis was carried out in 109 patients, 49 of whom had cancer and 60 benign disease. 
Although this was a small, highly selected minority of patients, sensitivity of 0.98 (48 of 49) 
and specificity of 0.73 (44 of 60) were observed. The biological and medical implications of 
these circumstantial observations warrant further research using a formal study design. 
In conclusion, the present study provides further evidence of the fact that TRAP assay and 
FISH analysis play a potential role in the diagnostic work-up of urinary symptoms. Further 
research is needed to develop an effective multimodal approach. 
 
Second study 
 
Numerous articles have been published on the role of DNA alterations, such as genetic and 
epigenetic modifications in urine sediment, as biomarkers for early bladder cancer 
diagnosis74but very few studies have investigated the potential role of DNA in urine 
supernatant63-65.  
Cell-free DNA can easily be detected in very small volumes of urine and, unlike RNA or 
enzymes, has good stability. Secondly, cell-free DNA in body fluids is suitable for multiple 
analyses74, such as mutations, microsatellite loss of heterozygosity (LOH), and epigenetic 
alterations60 . In  this study, DNA integrity, a specific marker of nonapoptotic cancer cells 
was evaluated. As demonstrated by Chang and coworkers in 200764 and confirmed by 
Zancan et al. in 200965 cell-free DNA is not sufficiently accurate to correctly distinguish 
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between bladder cancer patients and healthy individuals. Then, DNA integrity a specific 
marker of nonapoptotic cancer cells, was concentrated, and only long DNA fragments was 
analyzed. Moreover, to increase the diagnostic accuracy of the test, the analysis on 3 specific 
sequences longer than 250 bp located at loci: 8q24.21 (c-Myc), 17q12.1 (HER2), and 20q13.2 
(BCAS1) was performed. These regions were selected because they are known to be 
amplified during bladder cancer development and progression74,75. UCF DNA integrity in 
urine is a determining feature for bladder cancer detection, with a higher sensitivity than 
conventional noninvasive cytology, especially for low-grade tumours. Such a characteristic is 
important for a new marker aimed at early bladder cancer diagnosis76. This line of research 
has already been pursued by our group in healthy individuals and cancer patients21,41,42 and in 
a clinical setting of symptomatic patients70. The symptomatic subgroup and individuals 
exposed to industrial chemicals are the main candidates for a screening program of low 
prevalence tumour histotypes77,78. Interestingly, in the present study, we found similar 
specificity in healthy individuals and symptomatic patients, suggesting that the test can also 
accurately identify tumours among benign disease with a low number of false positives. The 
high percentage of true positives is probably ascribable to the analysis of DNA integrity at 3 
genomic regions specifically amplified in bladder cancer. 
DNA status index (DSI) i.e., the ratio between DNA integrity of the 3 genes (c-Myc, HER2, 
BCAS1) and the short fragment STOX1 were analyzed. As expected, a positive correlation 
was found between the DSI and the presence of bladder cancer (data not shown). These 
results seem to indicate that in cancer samples, DNA predominantly exists as long fragments, 
suggesting that its origin is mainly from nonapoptotic cells. 
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It has recently been demonstrated that the combination of 2 or more urine assays improves 
the detection of urothelial cancers79. Therefore, in an attempt to increase sensitivity, a 
diagnostic algorithm in which cytology and UCF DNA integrity were tested sequentially was 
constructed. In our series of symptomatic individuals, this combination demonstrated 
improved sensitivity compared with that of each test alone. Moreover, sensitivity and 
specificity were similar to those obtained  using the combination of urine telomerase activity, 
cytology, and FISH. Our results have an important additional value in terms of the 
cost/benefit ratio. In fact, in the present study, only 2 tests were combined rather than 3; 
secondly, UCF DNA integrity analysis is easier to perform and to interpret than FISH 
UroVysion, which requires the consensus of 2 experts. Results for UCF DNA integrity are 
obtainable in a relatively short time (about 2 working days) and, most importantly, this 
approach costs less than one-third of the cost of FISH UroVysion. In addition, only small 
volumes (2 ml) of urine are required for the evaluation of cell-free DNA integrity and this 
analysis, unlike TRAP assay70, is not affected by the presence of contaminants, such as 
inflammatory cells, as shown by the high specificity in symptomatic patients. Important 
limitations of the present work are the relatively small case series and the fact that both 
cytology and UCF DNA results were not available for all patients. However, such limitations 
are acceptable in a pilot study of a new diagnostic approach. A confirmatory study on a 
larger case series is ongoing to validate these results.  
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8. CONCLUSIONS 
 
In conclusion, these preliminary results are promising and pave the way towards new 
molecular approaches for the early noninvasive diagnosis of bladder cancer, which could be 
used in combination with or as an alternative to voided cytology. In particular, these 
diagnostic  biomarkers appear to show  great potential if used in high risk subgroups such as 
symptomatic patients.  
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